CervoMed Inc (NASDAQ: CRVO) has experienced a decline in its stock price by -8.73 compared to its previous closing price of 13.18. However, the company has seen a fall of -14.13% in its stock price over the last five trading days. globenewswire.com reported 2024-10-02 that Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications” Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications”
Is It Worth Investing in CervoMed Inc (NASDAQ: CRVO) Right Now?
The 36-month beta value for CRVO is also noteworthy at 1.61. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRVO is 5.35M, and at present, short sellers hold a 22.06% of that float. The average trading volume of CRVO on October 23, 2024 was 83.84K shares.
CRVO’s Market Performance
The stock of CervoMed Inc (CRVO) has seen a -14.13% decrease in the past week, with a -22.88% drop in the past month, and a -18.99% fall in the past quarter. The volatility ratio for the week is 8.90%, and the volatility levels for the past 30 days are at 9.49% for CRVO. The simple moving average for the past 20 days is -12.80% for CRVO’s stock, with a -28.48% simple moving average for the past 200 days.
Analysts’ Opinion of CRVO
Many brokerage firms have already submitted their reports for CRVO stocks, with Chardan Capital Markets repeating the rating for CRVO by listing it as a “Buy.” The predicted price for CRVO in the upcoming period, according to Chardan Capital Markets is $55 based on the research report published on September 18, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CRVO reach a price target of $35. The rating they have provided for CRVO stocks is “Overweight” according to the report published on July 26th, 2024.
Canaccord Genuity gave a rating of “Buy” to CRVO, setting the target price at $50 in the report published on February 15th of the current year.
CRVO Trading at -21.64% from the 50-Day Moving Average
After a stumble in the market that brought CRVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.40% of loss for the given period.
Volatility was left at 9.49%, however, over the last 30 days, the volatility rate increased by 8.90%, as shares sank -20.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.82% lower at present.
During the last 5 trading sessions, CRVO fell by -14.13%, which changed the moving average for the period of 200-days by +27.98% in comparison to the 20-day moving average, which settled at $13.80. In addition, CervoMed Inc saw 57.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRVO starting from ELDER WILLIAM ROBERT, who purchase 1,000 shares at the price of $18.16 back on Aug 27 ’24. After this action, ELDER WILLIAM ROBERT now owns 1,267 shares of CervoMed Inc, valued at $18,160 using the latest closing price.
Stock Fundamentals for CRVO
Current profitability levels for the company are sitting at:
- -1.11 for the present operating margin
- 0.23 for the gross margin
The net margin for CervoMed Inc stands at -0.52. The total capital return value is set at -0.22. Equity return is now at value -15.71, with -14.64 for asset returns.
Currently, EBITDA for the company is -7.81 million with net debt to EBITDA at 0.93. When we switch over and look at the enterprise to sales, we see a ratio of 9.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.73.
Conclusion
In summary, CervoMed Inc (CRVO) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
